Identifikacija, strukturna karakterizacija i određivanje palbocikliba primjenom HPLC-DAD-MS/MS metode

master's thesis

• Title (english): Identification, structural elucidation and determination of palbociclib using HPLC-DAD-MS/MS method
• Author: Ivana Ivanušić
• Mentor: Miranda Sertić (mentor)
• Committee member: Miranda Sertić (predsjednik povjerenstva)
• Committee member: Biljana Nigović (član povjerenstva)
• Granter: University of Zagreb; Faculty of Pharmacy and Biochemistry; (Department of pharmaceutical analysis); Zagreb
• Defense date and country: 2017-11-03, Croatia
• Scientific / art field, discipline and subdiscipline: BIOMEDICINE AND HEALTHCARE; Pharmacy; Pharmacy

Abstract

Rak dojke je najčešća vrsta karcinoma u žena diljem svijeta i drugi najčešći rak u cijeloj populaciji, a svake je godine uzrok smrti čak pola milijuna ljudi (većinom žena). Najčešći tip raka dojke je ER-pozitivni, HER2-negativni rak dojke (74% slučajeva) koji ujedno ima i najbolju prognozu ako liječenje počne na vrijeme.
Palbociklib je novi lijek (prvi u svojoj skupini) odobren za liječenje upravo tog tipa raka dojke, a koristi se u kombinaciji s letrozolom ili fulvestrantom. Selektivan je i reverzibilan inhibitor ciklin-ovisnih kinaza 4 i 6 te njihovom blokadom usporava rast i proliferaciju ER-pozitivnih stanica raka dojke. Palbociklib predstavlja značajni napredak u terapiji karcinoma dojke jer dokazano produljuje vrijeme preživljenja oboljelih žena bez progresije bolesti.
Ovim je radom uspješno identificiran, strukturno okarakteriziran i određen palbociklib u uzorku aktivne ljekovite tvari pomoću tekućinske kromatografije visoke djelotvornosti spregnute s masenim spektrometrom. Identificiran je preko vremena zadržavanja (tR = 5,6 min), UV-Vis spektra i ESI-MSn spektara, a za kvantitativno određivanje je korištena metoda vanjskog standarda.

Abstract (english)

Breast cancer is the most common cancer in women worldwide and second most common cancer in entire population. Every year it is the cause of death of a half million people (mostly women). Most common type of cancer is ER-positive, HER2-negative breast cancer (74% of all cases) which also has the best prognosis when treated on time.
Palbociclib is a new drug (first in his class) approved as a treatment for that particular type of cancer and it is used in combination with letrozole or fulvestrant. It is a selective and reversible inhibitor of the cyclin-dependent kinases 4 and 6; therefore, it slows down the growth and proliferation of ER-positive breast cancer cells. Palbociclib represents a big breakthrough in breast cancer treatment because it prolongs the progression-free survival in women.
In this thesis, palbociclib was successfully identified, structurally elucidated and quantitatively determined from sample of active pharmaceutical ingredient using high performance liquid chromatography combined with mass spectrometry. It was identified through retention time (tR = 5,6 min), UV-Vis spectrum and ESI-MSn spectra and quantitatively determined using a calibration curve method.

• Keywords: palbociklib; HPLC-DAD-MS/MS; tekućinska kromatografija; masena spektrometrija
• Keywords (english): palbociclib; HPLC-DAD-MS/MS; liquid chromatography; mass spectrometry
• Language: croatian
• URN:NBN: urn:nbn:hr:163:753310
• Study programme: Title: Pharmacy; Study programme type: university; Study level: integrated undergraduate and graduate; Academic / professional title: magistar/magistra farmacije (magistar/magistra farmacije)
• Type of resource: Text
• File origin: Born digital
• Access conditions: Open access
• Created on: 2021-04-19 12:56:42